Recent stock performance and context

Ionis Pharmaceuticals (IONS) has seen its stock give back some ground recently, with the price down about 2% over the past week and roughly 1% over the past month, against a 7% decline over the past 3 months.

Zooming out, Ionis Pharmaceuticals’ share price has cooled recently. However, its 1-year total shareholder return of 121.19% and 3-year total shareholder return of 89.41% indicate that longer term momentum has been strong, even as short term sentiment has softened around growth potential and risk.

If this kind of move has you thinking about where else growth stories might emerge, it could be worth scanning 32 healthcare AI stocks for other healthcare companies using AI that may interest you.

So with Ionis shares cooling after a strong multi year run, yet trading at a discount to an average analyst price target and some models of intrinsic value, are you looking at a fresh opportunity, or a stock where future growth is already priced in?

Most Popular Narrative: 23.3% Undervalued

At a last close of $74.23 versus a narrative fair value of $96.73, the widely followed thesis sees Ionis Pharmaceuticals as materially mispriced, with that view anchored in detailed revenue and margin forecasts.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

Expanding addressable patient populations from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

Want to see how this story tries to turn heavy R&D spending into future earnings power? The narrative hinges on faster revenue compounding, rising margins, and a bold profit multiple that together support a higher fair value.

Result: Fair Value of $96.73 (UNDERVALUED)

However, this hinges on key approvals and pricing, and delays for drugs like olezarsen or sharper than expected price cuts in broader indications could quickly challenge that upbeat story.

Another View: What The Market Multiple Is Saying

The narrative fair value and analyst target hint at upside, but the current sales multiple tells a tougher story. Ionis trades on a P/S of 11.6x, which is richer than both the US Biotechs industry at 10.9x and a peer average of 4.3x, and well above a fair ratio of 4.7x that the market could move toward. For an investor, that gap can either look like a premium price for a promising pipeline or a valuation risk if sentiment cools.

Before leaning too hard on any single fair value, it can help to see what the numbers imply over different scenarios in the valuation breakdown, then judge whether the current premium feels justified for your own time horizon and risk tolerance. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and caution in this story feels familiar, it is worth checking the data yourself and moving quickly to form your own view. You can start with the 2 key rewards

Looking for more investment ideas?

If Ionis has sharpened your appetite for opportunity, do not stop here. Your next strong idea could be sitting just outside your current watchlist.

• Target potential value by scanning 50 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them yet.
• Prioritize strength by checking solid balance sheet and fundamentals stocks screener (45 results) where financial footing supports durability through different market conditions.
• Get ahead of the crowd by reviewing a screener containing 22 high quality undiscovered gems before broader attention arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.